Patents by Inventor James C. Paulson

James C. Paulson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230293711
    Abstract: The present invention provides methods for enhancing T cell activation and expansion, and methods for stimulating a T cell immune response in a subject. The methods of the invention involve the use of a targeting agent-enzyme conjugate that contains (a) a targeting moiety that specifically binds a cell surface molecule on T cells, and (b) a sialidase or enzymatically active fragment thereof. Also provided in the invention are targeting agent-enzyme conjugates that can be used in the therapeutic methods, including antibody conjugates that are formed of a sialidase and a T cell targeting antibody (e.g., an anti-PD1 antibody).
    Type: Application
    Filed: July 21, 2021
    Publication date: September 21, 2023
    Inventors: James C. PAULSON, Landon J. EDGAR, Andrew J. THOMPSON, Chika KIKUCHI, Brett GARABEDIAN, Xiaoshuang WANG, Eleanor BASHIAN
  • Publication number: 20230037822
    Abstract: Described herein are Siglec ligand-antibody conjugates and compositions thereof that are useful for suppressing unwanted immune responses such as allergies and anaphylaxis.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 9, 2023
    Applicant: The Scripps Research Institute
    Inventors: James C. Paulson, Maidul Islam, Fabian Pfrengle, Matthew Macauley, Shiteng Duan, Britni Arlian
  • Patent number: 10994006
    Abstract: Compositions and methods are described herein that are useful for treating and inhibiting allergic conditions, including reducing the incidence of mast cell mediated anaphylaxis in subjects. The compositions include a carrier that displays an antigen and a Siglec ligand that binds to a Siglec on a mast cell.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: May 4, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: James C. Paulson, Shiteng Duan, Matthew MacAuley, Corwin Nycholat
  • Publication number: 20190151444
    Abstract: Compositions and methods are described herein that are useful for treating and inhibiting allergic conditions, including reducing the incidence of mast cell mediated anaphylaxis in subjects. The compositions include a carrier that displays an antigen and a Siglec ligand that binds to a Siglec on a mast cell.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 23, 2019
    Inventors: James C. Paulson, Shiteng Duan, Matthew MacAuley, Corwin Nycholat
  • Patent number: 9981023
    Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition thatco-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 29, 2018
    Assignee: The Scripps Research Institute
    Inventors: James C. Paulson, Matthew MacAuley, David Nemazee
  • Publication number: 20170165333
    Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition thatco-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
    Type: Application
    Filed: December 6, 2016
    Publication date: June 15, 2017
    Inventors: James C. Paulson, Matthew MacAuley, David Nemazee
  • Patent number: 9522183
    Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec)expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: December 20, 2016
    Assignee: The Scripps Research Institute
    Inventors: James C. Paulson, Matthew Macauley, David Nemazee
  • Patent number: 9326939
    Abstract: The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: May 3, 2016
    Assignee: The Scripps Research Institute
    Inventors: James C. Paulson, Weihsu Claire Chen, Norihito Kawasaki, Corwin Nycholat
  • Publication number: 20160060324
    Abstract: The present invention provides immune conjugates for inducing antigen specific immune tolerance to coagulation Factor VIII. The immune conjugates contain a FVIII protein or antigenic fragment that is conjugated to a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods of using the FVIII immune conjugates to induce immune tolerance to FVIII in a subject. Additionally provided in the invention are methods for treating bleeding disorders such as hemophilia A via the use of the FVIII immune conjugates and an unconjugated FVIII with coagulating activity.
    Type: Application
    Filed: April 18, 2014
    Publication date: March 3, 2016
    Inventors: James C. Paulson, Matthew Macauley, Fabian Pfrengle
  • Publication number: 20130171233
    Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
    Type: Application
    Filed: July 29, 2011
    Publication date: July 4, 2013
    Inventors: James C. Paulson, Matthew MacAuley, David Nemazee
  • Publication number: 20130164364
    Abstract: The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses.
    Type: Application
    Filed: July 29, 2011
    Publication date: June 27, 2013
    Inventors: James C. Paulson, Weihsu Claire Chen, Norihito Kawasaki, Corwin Nycholat
  • Patent number: 7220555
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: May 22, 2007
    Assignee: Neose Technologies, Inc.
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Publication number: 20030124645
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Application
    Filed: August 13, 2002
    Publication date: July 3, 2003
    Applicant: Neose Technologies, Inc.
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Publication number: 20030013636
    Abstract: The invention provides methods for inhibiting immune responses by inhibiting the biosynthesis of the sialyl galactosides that are involved in immune responses. In particular, B lymphocyte-mediated immune responses are mediated by interfering with synthesis of &agr;2,6 sialylgalactosides, while T lymphocyte-mediated immune responses are inhibited by blocking synthesis of &agr;2,3 sialylgalactosides. The inhibition is accomplished by, for example, inhibiting the activity of a glycosyltransferase involved in synthesis of the respective sialyl galactoside.
    Type: Application
    Filed: April 23, 2002
    Publication date: January 16, 2003
    Applicant: Cytel Corporation
    Inventors: Jamey D. Marth, James C. Paulson
  • Publication number: 20020160460
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Application
    Filed: February 21, 2002
    Publication date: October 31, 2002
    Applicant: Neose Technologies, Inc.
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Publication number: 20020142370
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Application
    Filed: February 21, 2002
    Publication date: October 3, 2002
    Applicant: Neose Technologies, Inc.
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Publication number: 20020119516
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Application
    Filed: November 9, 2001
    Publication date: August 29, 2002
    Applicant: Cytel Corporation
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Patent number: 6399336
    Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: June 4, 2002
    Assignee: Neose Technologies, Inc.
    Inventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
  • Patent number: 6376475
    Abstract: The invention provides methods for inhibiting immune responses by inhibiting the biosynthesis of the sialyl galactosides that are involved in immune responses. In particular, B lymphocyte-mediated immune responses are mediated by interfering with synthesis of &agr;2,6 sialylgalactosides, while T lymphocyte-mediated immune responses are inhibited by blocking synthesis of &agr;2,3 sialylgalactosides. The inhibition is accomplished by, for example, inhibiting the activity of a glycosyltransferase involved in synthesis of the respective sialyl galactoside.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: April 23, 2002
    Assignee: Abaron Biosciences, Inc.
    Inventors: Jamey D. Marth, James C. Paulson
  • Patent number: 6033667
    Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: March 7, 2000
    Assignee: Cytel Corporation
    Inventors: Robert W. Chesnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn